Sujata Patil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sujata Patil has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Darren Richard Feldman
Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications- Robert J. Motzer
Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021
6 shared publications Robert John Motzer
Memorial Sloan-Kettering Cancer Center, New York, NY
5 shared publications- Clifford A. Hudis
American Society of Clinical Oncology, Alexandria, VA
4 shared publications - George J. Bosl
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
4 shared publications Martin Henner Voss
Memorial Sloan Kettering Cancer Center, New York, NY
4 shared publications
Latest Publications
- Open Access
LONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
Background: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer. Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI. Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery. Conclusions: Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.
Open AccessLONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
Background: To determine the longitudinal impact of adjuvant chemotherapy and tamoxifen-only treatments on ovarian reserve by serum anti-Mullerian hormone (AMH) levels in women with breast cancer. Methods: One-hundred-and-forty-two women with a primary diagnosis of breast cancer were prospectively followed with serum AMH assessments before the initiation, and 12, 18 and 24 months after the completion of adjuvant chemotherapy or the start of tamoxifen-only treatment. The chemotherapy regimens were classified into Anthracycline-Cyclophosphamide-based (AC-based) and Cyclophosphamide-Methotrexate+5-Fluorouracil (CMF). Longitudinal data were analyzed by mixed effects model for treatment effects over time, adjusting for baseline age and BMI. Results: Both chemotherapy regimens resulted in significant decline in ovarian reserve compared to the tamoxifen-only treatment (p<0.0001 either regimen vs. tamoxifen for overall trend). AMH levels sharply declined at 12 months but did not show a significant recovery from 12 to 18 and 18 to 24 months after the completion of AC-based or CMF regimens. The degree of decline did not differ between the two chemotherapy groups (p=0.53). In contrast, tamoxifen-only treatment did not significantly alter the age-adjusted serum AMH levels over the 24-month follow up. Likewise, the use of adjuvant tamoxifen following AC-based regimens did not affect AMH recovery. Conclusions: Both AC-based and CMF regimens significantly compromise ovarian reserve, which does not recover during the 12-24-month post-chemotherapy follow up. In contrast, tamoxifen treatment does not seem to alter ovarian reserve. This novel information should be valuable for fertility preservation counselling and in assessing future reproductive potential of breast cancer survivors.
- Open Access
Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ
BACKGROUND: The current study was conducted to examine the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy (RT) in women with ductal carcinoma in situ (DCIS) undergoing breast‐conserving surgery (BCS).METHODS: Women with DCIS who were treated with BCS and RT from 1980 through 2010 were identified from a prospectively maintained database. IBTR rates, measured from the time of RT completion, were compared between those who initiated RT ≤8 weeks, >8 to 12 weeks, and >12 weeks after the completion of surgery. The association between RT timing and IBTR was evaluated by Kaplan‐Meier and log‐rank analyses; Cox modeling was used for multivariable analysis.RESULTS: A total of 1323 women met the inclusion criteria. The median follow‐up was 6.6 years, with 311 patients followed for ≥10 years. A total of 126 IBTR events occurred. Patients were categorized by RT timing: 806 patients (61%) with timing of ≤8 weeks, 386 patients (29%) with timing of >8 to 12 weeks, and 131 patients (10%) with timing >12 weeks. The 5‐year and 10‐year IBTR rates were 5.8% and 13.0%, respectively, for RT starting ≤8 weeks after surgery; 3.8% and 7.6%, respectively, for RT starting >8 to 12 weeks after surgery; and 8.8% and 23.0%, respectively, for an RT delay >12 weeks after surgery (P = .004). On multivariable analysis, menopause (hazard ratio [HR], 0.54; P = .0009) and endocrine therapy (HR, 0.45; P = .002) were found to be protective against IBTR, whereas a delay in RT >12 weeks compared with ≤8 weeks was associated with a higher risk of IBTR (HR, 1.92; P = .014). There was no difference in IBTR noted between RT initiation at ≤8 weeks and initiation at >8 to 12 weeks after BCS (P = .3).CONCLUSIONS: A delay in RT >12 weeks is associated with a significantly higher risk of IBTR in women undergoing BCS for DCIS. Efforts should be made to avoid delays in starting RT to minimize the risk of disease recurrence. Cancer 2018;124:46‐54. © 2017 American Cancer Society.
Open AccessDelay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ
BACKGROUND: The current study was conducted to examine the association between ipsilateral breast tumor recurrence (IBTR) and the timing of radiotherapy (RT) in women with ductal carcinoma in situ (DCIS) undergoing breast‐conserving surgery (BCS).METHODS: Women with DCIS who were treated with BCS and RT from 1980 through 2010 were identified from a prospectively maintained database. IBTR rates, measured from the time of RT completion, were compared between those who initiated RT ≤8 weeks, >8 to 12 weeks, and >12 weeks after the completion of surgery. The association between RT timing and IBTR was evaluated by Kaplan‐Meier and log‐rank analyses; Cox modeling was used for multivariable analysis.RESULTS: A total of 1323 women met the inclusion criteria. The median follow‐up was 6.6 years, with 311 patients followed for ≥10 years. A total of 126 IBTR events occurred. Patients were categorized by RT timing: 806 patients (61%) with timing of ≤8 weeks, 386 patients (29%) with timing of >8 to 12 weeks, and 131 patients (10%) with timing >12 weeks. The 5‐year and 10‐year IBTR rates were 5.8% and 13.0%, respectively, for RT starting ≤8 weeks after surgery; 3.8% and 7.6%, respectively, for RT starting >8 to 12 weeks after surgery; and 8.8% and 23.0%, respectively, for an RT delay >12 weeks after surgery (P = .004). On multivariable analysis, menopause (hazard ratio [HR], 0.54; P = .0009) and endocrine therapy (HR, 0.45; P = .002) were found to be protective against IBTR, whereas a delay in RT >12 weeks compared with ≤8 weeks was associated with a higher risk of IBTR (HR, 1.92; P = .014). There was no difference in IBTR noted between RT initiation at ≤8 weeks and initiation at >8 to 12 weeks after BCS (P = .3).CONCLUSIONS: A delay in RT >12 weeks is associated with a significantly higher risk of IBTR in women undergoing BCS for DCIS. Efforts should be made to avoid delays in starting RT to minimize the risk of disease recurrence. Cancer 2018;124:46‐54. © 2017 American Cancer Society.
- Open Access
- 2 August 2017
- Published by Springer Nature in Breast Cancer Research
- Vol. 19 (1) , 1-8
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clinical activity. We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer. In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-positive metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15. Therapy was continued until disease progression or toxicity. The primary objective was to establish the safety and maximum tolerated dose and/or recommended phase II dose (RP2D) of this therapy. The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy. Dose escalation was completed for the two main cohorts without any observed dose-limiting toxicities. Nine patients received treatment. The median prior lines of anti-HER2 therapy numbered three (range 2–4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients. The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash. There were no grade 4 AEs related to ganetespib. The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients). The clinical benefit rate was 44% (4/9 patients). The median progression-free survival was 20 weeks (range 8–55). The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab. The combination was safe and well tolerated. Despite prior taxanes, pertuzumab, and T-DM1, clinical activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-positive metastatic breast cancer. ClinicalTrials.gov NCT02060253 . Registered 30 January 2014.
- 2 August 2017
- Published by Springer Nature in Breast Cancer Research
- Vol. 19 (1) , 1-8
Open AccessA phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance. Preclinical data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clinical activity. We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-positive metastatic breast cancer. In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-positive metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15. Therapy was continued until disease progression or toxicity. The primary objective was to establish the safety and maximum tolerated dose and/or recommended phase II dose (RP2D) of this therapy. The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy. Dose escalation was completed for the two main cohorts without any observed dose-limiting toxicities. Nine patients received treatment. The median prior lines of anti-HER2 therapy numbered three (range 2–4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients. The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash. There were no grade 4 AEs related to ganetespib. The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients). The clinical benefit rate was 44% (4/9 patients). The median progression-free survival was 20 weeks (range 8–55). The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab. The combination was safe and well tolerated. Despite prior taxanes, pertuzumab, and T-DM1, clinical activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-positive metastatic breast cancer. ClinicalTrials.gov NCT02060253 . Registered 30 January 2014.
- Open Access
- 1 June 2017
- Published by Elsevier in Journal of Bone Oncology
- Vol. 7, 32-37
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
- 1 June 2017
- Published by Elsevier in Journal of Bone Oncology
- Vol. 7, 32-37
Open AccessAssessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 4555
Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT).
4555 Background: GCT display totipotential differentiation ranging from pluripotent embryonal carcinoma to extraembryonic (choriocarcinoma, yolk sac) to somatic cell types (teratoma [T]). We hypothesized that long-term survival after platinum-based chemotherapy (PC) is dependent upon histology. Methods: Advanced GCT pts who received PC from 4/1975 to 5/1996 and had a pre-PC primary tumor specimen available were included. Each pre-PC cell type was reviewed and confirmed. Residual tumor size post-PC was recorded when available. Differences in cumulative incidence (CUI) of death due to disease (DOD) between histologic cell types and other baseline characteristics were evaluated using a competing risks approach and the Fine & Gray test. Results: Pre-PC primary tumor specimens (96% testis, 3% mediastinum) were available from 231 pts. Median age was 29 years (y) and median followup 17 y (range 0.3-35 y). 41 pts had pure seminoma; of the remaining 190 with nonseminomatous GCT (NSGCT), 81 had an element of T (n=29 mature T, n=42 immature T, n=10 both). At PC start, 60% of pts were IGCCCG good risk, 26% intermediate, and 13% poor with no difference for NSGCT based on presence vs. absence of T (p=0.53). Of 72 deaths, 50 were DOD, 20 from other causes, and 2 from unknown causes. The 5, 10, and 15 y CUI of death from any cause was 20%, 23%, and 26%, respectively. CUI of DOD at 5, 10 and 15 y was 18%, 20%, 22%, respectively. CUI of DOD at 2, 5, 10 and 15 y by histologic group is provided in the Table. Presence of T was associated with greater CUI of DOD vs. NSGCT without T (p=0.04) and mature T with a greater CUI of DOD vs. immature T (p=0.03). NSGCT pts with T were also more likely to have residual retroperitoneal disease >1cm after PC vs. those without T (50 vs. 4.2%; p=0.01). Conclusions: With long-term followup, the presence of an element of T, particularly mature T, in mixed NSGCT was associated with a higher risk of DOD than tumors without T, which have the same risk of DOD as pure seminoma. These data suggest that the presence of T in the primary tumor may be an important clinical predictor of long-term outcome in men with GCT. [Table: see text]
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 4555
Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT).
4555 Background: GCT display totipotential differentiation ranging from pluripotent embryonal carcinoma to extraembryonic (choriocarcinoma, yolk sac) to somatic cell types (teratoma [T]). We hypothesized that long-term survival after platinum-based chemotherapy (PC) is dependent upon histology. Methods: Advanced GCT pts who received PC from 4/1975 to 5/1996 and had a pre-PC primary tumor specimen available were included. Each pre-PC cell type was reviewed and confirmed. Residual tumor size post-PC was recorded when available. Differences in cumulative incidence (CUI) of death due to disease (DOD) between histologic cell types and other baseline characteristics were evaluated using a competing risks approach and the Fine & Gray test. Results: Pre-PC primary tumor specimens (96% testis, 3% mediastinum) were available from 231 pts. Median age was 29 years (y) and median followup 17 y (range 0.3-35 y). 41 pts had pure seminoma; of the remaining 190 with nonseminomatous GCT (NSGCT), 81 had an element of T (n=29 mature T, n=42 immature T, n=10 both). At PC start, 60% of pts were IGCCCG good risk, 26% intermediate, and 13% poor with no difference for NSGCT based on presence vs. absence of T (p=0.53). Of 72 deaths, 50 were DOD, 20 from other causes, and 2 from unknown causes. The 5, 10, and 15 y CUI of death from any cause was 20%, 23%, and 26%, respectively. CUI of DOD at 5, 10 and 15 y was 18%, 20%, 22%, respectively. CUI of DOD at 2, 5, 10 and 15 y by histologic group is provided in the Table. Presence of T was associated with greater CUI of DOD vs. NSGCT without T (p=0.04) and mature T with a greater CUI of DOD vs. immature T (p=0.03). NSGCT pts with T were also more likely to have residual retroperitoneal disease >1cm after PC vs. those without T (50 vs. 4.2%; p=0.01). Conclusions: With long-term followup, the presence of an element of T, particularly mature T, in mixed NSGCT was associated with a higher risk of DOD than tumors without T, which have the same risk of DOD as pure seminoma. These data suggest that the presence of T in the primary tumor may be an important clinical predictor of long-term outcome in men with GCT. [Table: see text]
- Open Access
Are there patients with T1 to T2, lymph node‐negative breast cancer who are “high‐risk” for locoregional disease recurrence?
BACKGROUND: Indications for postmastectomy radiotherapy (PMRT) in patients with T1 to T2, lymph node‐negative (N0) breast cancer with “high‐risk” features are controversial. The European Organization for Research and Treatment of Cancer (EORTC) 22922 and National Cancer Institute of Canada Clinical Trials Group MA20 trials reporting improved 10‐year disease‐free survival with lymph node irradiation included patients with high‐risk N0 disease, but, to the authors’ knowledge, benefits in patients receiving modern systemic therapy are uncertain.METHODS: The authors retrospectively identified patients with T1 to T2N0 disease who were treated with mastectomy from January 2006 through December 2011. High‐risk features included age .05). Receipt of systemic therapy decreased the LRR rate (hazard ratio, 0.40; P = .03). Although crude LRR rates increased from 3.8% to 9.4% with 1 versus ≥ 4 high‐risk features, the number of risk factors was not found to be significantly associated with LRR (P = .54).CONCLUSIONS: In the current study, a low crude LRR rate (4.7%) was observed in a large unselected cohort of patients with T1 to T2N0 breast cancer with high‐risk features who were treated with mastectomy and systemic therapy without PMRT. Although increasing tumor size and the omission of systemic therapy were found to be predictive, other features did not confer a higher LRR risk either independently or together, and do not by themselves mandate the use of PMRT in this patient population. Cancer 2017;123:2626‐33. © 2017 American Cancer Society.
Open AccessAre there patients with T1 to T2, lymph node‐negative breast cancer who are “high‐risk” for locoregional disease recurrence?
BACKGROUND: Indications for postmastectomy radiotherapy (PMRT) in patients with T1 to T2, lymph node‐negative (N0) breast cancer with “high‐risk” features are controversial. The European Organization for Research and Treatment of Cancer (EORTC) 22922 and National Cancer Institute of Canada Clinical Trials Group MA20 trials reporting improved 10‐year disease‐free survival with lymph node irradiation included patients with high‐risk N0 disease, but, to the authors’ knowledge, benefits in patients receiving modern systemic therapy are uncertain.METHODS: The authors retrospectively identified patients with T1 to T2N0 disease who were treated with mastectomy from January 2006 through December 2011. High‐risk features included age .05). Receipt of systemic therapy decreased the LRR rate (hazard ratio, 0.40; P = .03). Although crude LRR rates increased from 3.8% to 9.4% with 1 versus ≥ 4 high‐risk features, the number of risk factors was not found to be significantly associated with LRR (P = .54).CONCLUSIONS: In the current study, a low crude LRR rate (4.7%) was observed in a large unselected cohort of patients with T1 to T2N0 breast cancer with high‐risk features who were treated with mastectomy and systemic therapy without PMRT. Although increasing tumor size and the omission of systemic therapy were found to be predictive, other features did not confer a higher LRR risk either independently or together, and do not by themselves mandate the use of PMRT in this patient population. Cancer 2017;123:2626‐33. © 2017 American Cancer Society.
- 1 February 2017
- Published by Elsevier in Clinical Breast Cancer
- Vol. 17 (1) , 23-28
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis
- 1 February 2017
- Published by Elsevier in Clinical Breast Cancer
- Vol. 17 (1) , 23-28
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis
- 1 September 2016
- Published by Elsevier in European Journal of Radiology
- Vol. 85 (9) , 1651-1658
Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer
- 1 September 2016
- Published by Elsevier in European Journal of Radiology
- Vol. 85 (9) , 1651-1658
Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS1101
Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.
TPS1101 Background: Available in vitro chemosensitivity models are time consuming, difficult to scale and fail to recapitulate the complexities of the tumor microenvironment. As a result, ASCO advises against use of such assays to select treatment for patients (pts) based on lack of evidence that in vitro assays improve outcome rather than standard options guided by clinical trial data. We now pilot an in vivo methodology to test drug sensitivity in triple negative breast cancer (TNBC). An implantable, 820µm-diameter, cylindrical device has been created which contains 16 reservoirs, each loaded with either a single drug or combination. Using methods by Jonas et al (Sci Transl Med 2015), the device is implanted within a tumor via 18 gauge biopsy needle, and is retrieved 24 hours later by concentric needle biopsy using image guidance to capture the device and a surrounding column of tumor. Using multiparameter immunohistochemistry, the patient-specific antineoplastic effect for each drug/regimen may be assessed by staining the tumor surrounding the reservoirs for biomarkers such as cleaved-caspase3, ki67, phospho-H2AX and RAD51. Methods: This first-in-human study will assess the feasibility of device placement, retrieval, and in vivo measurement of drug activity in the pre-operative setting for 12 pts with ≥ T2 TNBC. Feasibility is defined as the ability to collect device data from at least 6 of the 12. Pts will then receive a standard of care neoadjuvant regimen, independent of device readout. We will obtain preliminary data regarding the ability of the device to predict response to neoadjuvant doxorubicin and cyclophosphamide (AC) by correlating histologic response of the tumor surrounding the AC-containing reservoir with residual tumor viability on a post-AC biopsy. Secondary endpoints include safety, reproducibility, interobserver variability. All analyses will be primarily descriptive and graphical in nature. If feasible, we plan a larger study to test whether the device-predicted response correlates with outcome, defined by residual cancer burden. Three patients have been enrolled. Clinical trial information: NCT02521363.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS1101
Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.
TPS1101 Background: Available in vitro chemosensitivity models are time consuming, difficult to scale and fail to recapitulate the complexities of the tumor microenvironment. As a result, ASCO advises against use of such assays to select treatment for patients (pts) based on lack of evidence that in vitro assays improve outcome rather than standard options guided by clinical trial data. We now pilot an in vivo methodology to test drug sensitivity in triple negative breast cancer (TNBC). An implantable, 820µm-diameter, cylindrical device has been created which contains 16 reservoirs, each loaded with either a single drug or combination. Using methods by Jonas et al (Sci Transl Med 2015), the device is implanted within a tumor via 18 gauge biopsy needle, and is retrieved 24 hours later by concentric needle biopsy using image guidance to capture the device and a surrounding column of tumor. Using multiparameter immunohistochemistry, the patient-specific antineoplastic effect for each drug/regimen may be assessed by staining the tumor surrounding the reservoirs for biomarkers such as cleaved-caspase3, ki67, phospho-H2AX and RAD51. Methods: This first-in-human study will assess the feasibility of device placement, retrieval, and in vivo measurement of drug activity in the pre-operative setting for 12 pts with ≥ T2 TNBC. Feasibility is defined as the ability to collect device data from at least 6 of the 12. Pts will then receive a standard of care neoadjuvant regimen, independent of device readout. We will obtain preliminary data regarding the ability of the device to predict response to neoadjuvant doxorubicin and cyclophosphamide (AC) by correlating histologic response of the tumor surrounding the AC-containing reservoir with residual tumor viability on a post-AC biopsy. Secondary endpoints include safety, reproducibility, interobserver variability. All analyses will be primarily descriptive and graphical in nature. If feasible, we plan a larger study to test whether the device-predicted response correlates with outcome, defined by residual cancer burden. Three patients have been enrolled. Clinical trial information: NCT02521363.
- 1 October 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (28_suppl) , 32
Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.
32 Background: Randomized trials of radiation after breast-conserving surgery (BCS) for DCIS found substantial rates of recurrence, with half of recurrences invasive. Decreasing local recurrence rates for invasive breast carcinoma have been observed, and are largely attributed to systemic therapy improvements. Here we examine recurrence rates after BCS for DCIS over 3 decades at one institution. Methods: We retrospectively reviewed a prospectively maintained database of DCIS patients undergoing BCS from 1978–2010. Cox proportional hazard models were used to investigate the association between treatment period and recurrence, controlling for other variables. Results: 363 (12%) recurrences among 2996 cases were observed. Median follow-up for patients without recurrence was 75 months (range 0–30 years); 732 were followed for ≥ 10 years. The 5-year recurrence rate for 1978–1998 was 13.6% versus 6.6% for 1999–2010 (hazard ratio [HR] 0.62, p < 0.0001). After controlling for age, family history, presentation (radiologic vs clinical), nuclear grade (non-high vs. high grade), necrosis, number of excisions ( ≤ 2 vs ≥ 3), margin status (positive/close vs negative), radiation, and endocrine therapy, treatment period remained significantly associated with recurrence, with later years associated with a lower HR (0.74, p = 0.02) compared to earlier. After stratification by radiation use, and adjustment for 7 other factors, the decrease in recurrence rates was limited to those without radiation (HR 0.62, p = 0.003); there was no decline in recurrence rates among those receiving radiation (HR 1.13, p = 0.6). Conclusions: Recurrence rates for DCIS have fallen over time. Increases in screen-detection, negative margins, and use of adjuvant therapies only partially explain the decrease. The unexplained decline is limited to women not receiving radiation, suggesting it is not due to changes in radiation efficacy, but may be due to improvements in radiologic detection and pathologic assessment. The lower recurrence risk observed for DCIS patients treated in more recent years is important for patient education, especially in view of the widely reported recent increase in use of mastectomy.
- 1 October 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (28_suppl) , 32
Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated with breast-conserving surgery over 30 years.
32 Background: Randomized trials of radiation after breast-conserving surgery (BCS) for DCIS found substantial rates of recurrence, with half of recurrences invasive. Decreasing local recurrence rates for invasive breast carcinoma have been observed, and are largely attributed to systemic therapy improvements. Here we examine recurrence rates after BCS for DCIS over 3 decades at one institution. Methods: We retrospectively reviewed a prospectively maintained database of DCIS patients undergoing BCS from 1978–2010. Cox proportional hazard models were used to investigate the association between treatment period and recurrence, controlling for other variables. Results: 363 (12%) recurrences among 2996 cases were observed. Median follow-up for patients without recurrence was 75 months (range 0–30 years); 732 were followed for ≥ 10 years. The 5-year recurrence rate for 1978–1998 was 13.6% versus 6.6% for 1999–2010 (hazard ratio [HR] 0.62, p < 0.0001). After controlling for age, family history, presentation (radiologic vs clinical), nuclear grade (non-high vs. high grade), necrosis, number of excisions ( ≤ 2 vs ≥ 3), margin status (positive/close vs negative), radiation, and endocrine therapy, treatment period remained significantly associated with recurrence, with later years associated with a lower HR (0.74, p = 0.02) compared to earlier. After stratification by radiation use, and adjustment for 7 other factors, the decrease in recurrence rates was limited to those without radiation (HR 0.62, p = 0.003); there was no decline in recurrence rates among those receiving radiation (HR 1.13, p = 0.6). Conclusions: Recurrence rates for DCIS have fallen over time. Increases in screen-detection, negative margins, and use of adjuvant therapies only partially explain the decrease. The unexplained decline is limited to women not receiving radiation, suggesting it is not due to changes in radiation efficacy, but may be due to improvements in radiologic detection and pathologic assessment. The lower recurrence risk observed for DCIS patients treated in more recent years is important for patient education, especially in view of the widely reported recent increase in use of mastectomy.